Most Recent
A Federal Court judge has questioned whether appeals from IP Australia should be allowed to proceed as hearings anew and not confined to the issues already run before the agency, in a ruling spanning 1,784 paragraphs that dismisses a challenge by chemical manufacturer SNF to a delegate's decisions granting two mining patents to rival BASF.
Generic pharmaceutical firm Sandoz has won a temporary stay of a $26.3 million judgment in a patent case as it awaits a decision by the Commissioner of Patents regarding a licence to make a cheaper version of the bestselling antidepressant Lexapro.
Baby food maker Bellamy's is not giving up its fight to limit the costs of two shareholder class actions against the company, lodging an appeal of a ruling that shut down its cost-capping bid as premature.
Legal action brought by the corporate regulator over withheld documents at the centre of an investigation into AMP's fees for no service conduct has settled, with law firm Clayton Utz producing the evidence on Thursday.
Chemical giant BASF is appealing an IP Australia ruling that allowed US-based Lubrizol Corporation to amend certain claims of its patent for an improved fuel additive.
Australian automotive electronics developer Directed Electronics OE has won access to documents seized from rivals it claims misappropriated its confidential information and infringed its copyright to gain $3.6 million in secret commissions.
A judge has rejected a bid by Bellamy's to limit the recoverable costs of rival law firms running joint class actions against the baby food maker, saying he would deal with any unjustified duplication later, not now.
Maurice Blackburn has persuaded a judge to lift a temporary injunction that blocked the law firm from going ahead with plans to unveil a replica of the iconic New York statue, Fearless Girl, at Melbourne's Federation Square for International Women's Day.
The Australian Competition and Consumer Commission has dropped its claims of collusion against rail freight companies Pacific National and Aurizon, as the trial in its competition case wraps up this week.
Biotech company Cryosite has agreed to pay $1.05 million to settle the competition regulator's landmark case alleging it jumped the gun on a proposed merger agreement with rival Cell Care.